[Corrigendum] Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑&alpha; and TGF‑&beta; in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial | Zendy

Yasuyoshi Miyata | Zendy; Kyohei Araki | Zendy; Kojiro Ohba | Zendy; Tomhiro Mastuo | Zendy; Yuichiro Nakamura | Zendy; Tsutomu Yuno | Zendy; Yuta Mukai | Zendy; Asato Otsubo | Zendy; Kensuke Mitsunari | Zendy; Yasushi Mochizuki | Zendy; Hideki Sakai | Zendy

Open Access

[Corrigendum] Oral intake of royal jelly improves anti‑cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF‑α and TGF‑β in renal cell carcinoma: A preliminary study based on a randomized double‑blind clinical trial

Author(s) -

Yasuyoshi Miyata,

Kyohei Araki,

Kojiro Ohba,

Tomhiro Mastuo,

Yuichiro Nakamura,

Tsutomu Yuno,

Yuta Mukai,

Asato Otsubo,

Kensuke Mitsunari,

Yasushi Mochizuki,

Hideki Sakai

Publication year - 2020

Publication title -

molecular and clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.442

H-Index - 7

eISSN - 2049-9469

pISSN - 2049-9450

DOI - 10.3892/mco.2020.2148

Subject(s) - oncogene , molecular medicine , renal cell carcinoma , cancer , alpha (finance) , adverse effect , cancer research , tumor necrosis factor alpha , beta (programming language) , medicine , cell , tgf beta signaling pathway , cell cycle , biology , transforming growth factor , biochemistry , surgery , construct validity , patient satisfaction , computer science , programming language

[This corrects the article DOI: 10.3892/mco.2020.2099.].

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research